Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study

@article{Sheldon2016PharmacokineticsPA,
  title={Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study},
  author={Eric G Sheldon and Martin Schwickart and Jinwei Li and Keunpyo Kim and Sarah Crouch and Shaista Parveen and Chris Kell and Claire E Birrell},
  journal={Advances in Therapy},
  year={2016},
  volume={33},
  pages={225-251}
}
  • Eric G Sheldon, Martin Schwickart, +5 authors Claire E Birrell
  • Published in Advances in Therapy 2016
  • Medicine
  • IntroductionThe anti-IgE therapy omalizumab is currently licensed for the treatment of moderate to severe allergic asthma and chronic idiopathic urticaria. Owing to limitations in the use of omalizumab, a need exists for optimized anti-IgE therapies to broaden clinical indications and patient populations, and to improve dosing schedules. The objective of this phase I, randomized, placebo/omalizumab-controlled, first-in-human, dose-escalation study was to evaluate the pharmacokinetics… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    2
    Twitter Mentions

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 12 CITATIONS

    Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

    VIEW 3 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    The use of biologics for immune modulation in allergic disease

    VIEW 1 EXCERPT

    Systemic Treatment for Severe Atopic Dermatitis

    VIEW 1 EXCERPT
    CITES BACKGROUND

    An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases

    VIEW 1 EXCERPT
    CITES RESULTS

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 30 REFERENCES

    Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

    VIEW 13 EXCERPTS
    HIGHLY INFLUENTIAL

    Atopic Dermatitis: Natural History, Diagnosis, and Treatment

    VIEW 1 EXCERPT
    HIGHLY INFLUENTIAL

    Omalizumab in asthma: an update on recent developments.

    VIEW 1 EXCERPT

    The production and regulation of IgE by the immune system

    VIEW 1 EXCERPT